OakChart

Cel-Sci Corp

CVMHealthcare·Biotechnology·USA·Nano·AMEX·Nov 11 • 12:44 PM ET

1.33-0.08 (-5.89%)
2026-11-11 18:46 CET
Market cap
24.80 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-22.70 USD m
Free cash flow, TTM
-16.75 USD m
EPS diluted, TTM
-2.58
P/E
-
Compare

Price

CVM against its 20, 50 and 200-day averages
2050200earnings
2.004.006.002.3M4.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CVMclose 1.3320-day 1.5150-day 1.68200-day 2.341.3352w low

83.0% under the 52-week high of 7.80 on 28 Nov 2025. 52-week low 0.89 on 12 May 2026. Last 15 sessions, 47.6% high to low

Profile

CVM
52-week range, 6% of the way up
0.897.80

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

IPODec 08, 1983
Beta0.61
ATR, 14d0.16
Rel volume0.62
Short float4.31%
Insider own6.94%
Inst own12.04%

Snapshot

6 groups

Valuation

Index-
Market Cap23.34M
Enterprise Value24.71M
Income-22.70M
Sales0.00M
Book/sh0.62
Cash/sh0.37
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPODec 08, 1983

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.13
P/C3.57
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.42
Current Ratio1.48
Debt/Eq0.72
LT Debt/Eq0.47
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.58
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y37.90% 23.99%
Sales past 3/5Y- -
EPS Y/Y TTM73.69%
Sales Y/Y TTM-
EPS Q/Q65.72%
Sales Q/Q-
EarningsAug 17 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own6.94%
Insider Trans69.36%
Inst Own12.04%
Inst Trans9.45%
ROA-108.91%
ROE-252.53%
ROIC-140.57%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-12.26%
SMA50-20.85%
SMA200-43.35%
Trades-

Technical

Shs Outstand17.59M
Shs Float16.37M
Short Float4.31%
Short Ratio4.03
Short Interest0.71M
52W High7.80 -82.99%
52W Low0.89 49.10%
Volatility10.41% 9.51%
ATR (14)0.16
RSI (14)38.90
Beta0.61
Rel Volume0.62
Avg Volume175.33K
Volume56,732

Performance

Perf Week-3.84%
Perf Month-24.17%
Perf Quarter-10.94%
Perf Half Y10.58%
Perf YTD-74.77%
Perf Year-81.26%
Perf 3Y-98.11%
Perf 5Y-99.63%
Perf 10Y-99.39%
Recom1.00
Target Price10.00
Prev Close1.41
Price1.33
Change %-5.89%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Jan 13, 2020InitiatedHH.C. WainwrightBuy$18+1,256.4%
Mar 02, 2015InitiatedDDawson JamesBuy$3+126.1%

Peers

Mkt cap
TickerCompanyMkt cap
PDSBPDS Biotechnology Corp105.53M
IMMPImmutep Limited ADR26.90M
IMNNImunon Inc4.32M
AIMAIM ImmunoTech Inc6.13M
BCTXBriaCell Therapeutics Corp32.74M
SLSSELLAS Life Sciences Group Inc1.72B
GLSIGreenwich LifeSciences Inc244.03M
ELTXElicio Therapeutics Inc44.44M
MAIAMAIA Biotechnology Inc65.15M
INMBINmune Bio Inc34.98M

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
KERSTEN GEERT RChief Executive OfficerAug 25 '26Buy1.38100,000138,000316,142Aug 26 08:32 AM
KERSTEN GEERT RChief Executive OfficerMay 14 '26Buy1.20300,000360,000311,547May 18 08:03 AM
KERSTEN GEERT RChief Executive OfficerMay 13 '26Buy1.19100,000119,000222,497May 14 08:56 AM
KERSTEN GEERT RChief Executive OfficerJan 22 '26Buy5.2638,023200,001120,815Jan 26 08:23 AM
KERSTEN GEERT RChief Executive OfficerDec 04 '25Buy5.968,38949,99881,794Dec 05 08:48 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 206
  • CEL-SCI's Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research (Business Wire)
  • CEL-SCI Presents New Phase 3 Multikine Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival (Business Wire)
  • CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology (Business Wire)
  • CEL-SCI Reports Fiscal Third Quarter 2026 Results (Business Wire)
  • Cel-Sci: Fiscal Q3 Earnings Snapshot (Associated Press)
  • Loading…
  • CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study (Business Wire) +8.80%
  • Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients (Business Wire) +7.02%
  • CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month (Stocktwits) -6.48%
  • Cel-Sci: Fiscal Q2 Earnings Snapshot (Associated Press) +10.00% +20.28%
  • Cel-Sci: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +8.37%
  • CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025 (TMX Newsfile)
  • CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference (TMX Newsfile)
  • CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-08-17-0.470--0.4700.00--
2026Q22026-05-18-0.670--0.6700.00--
2026Q12026-02-18-0.680--0.6820.00--
2025Q32025-08-14-1.360--1.3650.00--
2025Q22025-05-14-2.400--2.3320.00--
2025Q12025-02-18-3.300--3.2480.00--
2024Q32024-08-15-4.200--3.8100.00--
2024Q22024-05-16-4.200--4.1790.00--
2024Q12024-02-15-4.200--4.1530.00--
2023Q42023-12-226.300--4.873-0.00-
2023Q32023-08-11-17.100-4.500-5.6720.000.001
2023Q22023-05-12-5.700-5.100-5.7420.000.001
2023Q12023-02-15-5.400-4.800-5.5420.000.001
2022Q42022-12-28-6.300-4.500-6.2810.000.001
2022Q32022-08-15-6.900-4.500-6.8980.000.001
2022Q22022-05-13-6.900-4.650-6.8340.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2016FY-67.500--70.9730.29-
2017FY-57.300-34.200-54.6010.070.10
2018FY-56.100--56.1680.48-
2019FY-21.300-19.200-21.3010.460.50
2020FY-24.600-23.100-24.6920.560.60
2021FY-27.900-23.700-26.8270.000.10
2022FY-26.100-19.800-26.1630.000.00
2023FY-21.900-21.300-21.8300.000.00
2024FY-15.300-19.800-15.3000.000.00
2025FY-3.580-4.510-6.2660.000.00
2026FY--4.160--0.00
2027FY--0.920--18.98

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026FYS2025-12-291000.000.000.00
2026FYS2025-12-191000.000.000.00
2026FYS2025-10-312004.690.009.38
2026FYS2025-08-291009.389.389.38
2026FYR2025-12-29100-4.16-4.16-4.16
2026FYR2025-12-19100-4.16-4.16-4.16
2026FYR2025-10-31200-3.50-4.16-2.84
2026FYR2025-08-29100-2.84-2.84-2.84
2026FYE2025-12-29100-4.16-4.16-4.16
2026FYE2025-12-19100-4.16-4.16-4.16
2026FYE2025-10-31200-3.50-4.16-2.84
2026FYE2025-08-29100-2.84-2.84-2.84
2025FYS2025-11-112000.000.000.00
2025FYS2025-11-102000.000.000.00

Estimate history

EPS, annual-54.601-56.168-21.301-24.692-26.827-26.163-21.83-14.943-6.266-2.5828
Period201720182019202020212022202320242025TTM
EPS, quarterly-3.81-2.873-3.248-2.332-1.365-0.761-0.682-0.672-0.468
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00.4770.4630.559000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.3970.9341.1741.2911.441.4481.5812.1268.01617.589
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.8092.1262.4362.8125.3218.0168.428.49317.589
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.560.460.48
Cost of Goods Sold Incl. D&A3.833.893.973.963.880.50---
Gross Profit-3.83-3.89-3.97-3.96-3.88-0.50---
Selling, General and Administrative Excl. Other18.4620.9222.3827.5232.1835.7027.3820.0216.60
Research and Development14.8015.8918.1622.4725.3623.1117.8412.6610.91
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-22.29-24.81-26.35-31.48-36.06-36.19-28.99-20.20-16.77
Interest Expense0.440.650.750.681.081.151.041.804.22
Unusual Expense-0.010.000.000.00-0.340.701.164.1614.15
Net Income Before Taxes-22.70-25.41-26.92-32.19-36.70-36.36-30.26-22.13-31.84
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-22.70-25.41-26.92-32.19-36.70-36.36-30.26-22.13-31.84
Net Income From Continuing Operations-22.70-25.41-26.92-32.19-36.70-36.36-30.26-22.13-31.84
Net Income-22.70-25.41-26.92-32.19-36.70-36.36-30.26-22.13-31.84
EPS (Recurring)-1.87-6.27-15.31-21.83-26.33-26.47-24.03-18.50-38.69
EPS (Basic, Before Extraordinaries)-2.58-6.27-14.94-21.83-26.16-26.83-24.69-21.30-56.17
EPS (Diluted)-2.58-6.27-14.94-21.83-26.16-26.83-24.69-21.30-56.17
EBITDA-18.46-20.92-22.38-27.52-32.18-35.70-26.83-19.56-16.12
Non-Operating Income (Expense)0.010.050.18-0.040.111.680.934.023.30
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.791.914.276.2911.3913.6910.114.432.74
Price To Sales Ratio------838.93602.26144.51
Operating Margin-------5,188.28-4,364.11-3,519.47
Net Margin-------5,415.64-4,783.24-6,680.68
Shares Outstanding17.598.022.131.581.451.441.291.170.93
Market Capitalization24.8024.8067.6155.94134.26474.85493.81314.9779.26

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.950.960.960.960.960.971.000.99
Gross Profit-0.95-0.96-0.96-0.96-0.96-0.97-1.00-0.99
Selling, General and Administrative Excl. Other4.614.374.405.074.535.425.905.13
Research and Development3.653.773.683.703.744.014.434.48
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.56-5.33-5.37-6.03-5.49-6.39-6.89-6.12
Interest Expense0.110.120.090.130.170.180.170.17
Unusual Expense0.000.000.00-0.010.000.000.000.00
Net Income Before Taxes-5.67-5.47-5.47-6.10-5.66-6.57-7.07-6.11
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.67-5.47-5.47-6.10-5.66-6.57-7.07-6.11
Net Income From Continuing Operations-5.67-5.47-5.47-6.10-5.66-6.57-7.07-6.11
Net Income-5.67-5.47-5.47-6.10-5.66-6.57-7.07-6.11
EPS (Recurring)-0.47-0.67-0.68-0.76-1.36-2.33-3.25-2.87
EPS (Basic, Before Extraordinaries)-0.47-0.67-0.68-0.76-1.36-2.33-3.25-2.87
EPS (Diluted)-0.47-0.67-0.68-0.76-1.36-2.33-3.25-2.87
EBITDA-4.61-4.37-4.40-5.07-4.53-5.42-5.90-5.13
Non-Operating Income (Expense)0.00-0.02-0.010.050.000.00-0.010.19
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.450.450.440.440.070.690.710.73
Shares Outstanding17.598.498.428.025.322.812.442.13
Market Capitalization24.8027.1542.1673.5411.7619.4329.2367.61

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments10.954.744.1522.6742.2115.518.4410.312.37
Short Term Receivables0.000.000.000.000.050.050.060.120.22
Inventories0.301.022.252.002.010.820.780.650.67
Other Current Assets0.340.300.520.761.001.310.520.360.98
Total Current Assets11.606.066.9225.4445.2717.709.8111.444.24
Net Property, Plant & Equipment12.9016.9821.0224.7128.4120.8515.8316.2216.79
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.120.170.200.210.280.310.310.260.22
Other Assets3.543.792.390.161.911.671.671.671.67
Total Assets28.1626.9930.5350.5275.8740.5427.6229.5922.92
Short Term Debt Incl. Current Port. of LT Debt2.442.241.971.730.701.070.000.000.99
Accounts Payable1.061.452.011.621.682.021.595.748.20
Other Current Liabilities1.630.931.611.311.561.171.433.481.65
Total Current Liabilities5.134.625.594.663.944.273.029.2310.84
Long Term Debt6.949.3811.6013.5715.2712.8713.5113.3813.21
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.120.120.120.120.123.685.966.982.20
Total Liabilities12.2014.1217.3118.3619.3420.8122.4929.5926.26
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity15.9612.8713.2132.1656.5319.735.130.00-3.34
Total Shareholders Equity15.9612.8713.2132.1656.5319.735.130.00-3.34
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity15.9612.8713.2132.1656.5319.735.130.00-3.34
Total Liabilities & Stockholders Equity28.1626.9930.5350.5275.8740.5427.6229.5922.92
Book Value Per Share1.996.058.3622.2139.2515.284.370.00-8.41
Tangible Book Value Per Share1.985.978.2322.0639.0615.044.11-0.28-8.97
Price to Book Ratio2.265.253.784.178.4025.0361.35-63.32-3.01
Return on Assets-92.16-93.60-79.44-58.07-62.47-88.78-77.38-121.26-60.08
Return on Equity-176.32-206.43-141.89-82.75-95.36-243.40-862.18--
Return on Invested Capital-110.96-120.99-129.72-80.25-50.64-92.82-118.74-237.93-145.45
Quick Ratio2.201.090.845.0210.993.962.991.170.33
Current Ratio2.261.311.245.4511.504.153.251.240.39

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-22.70-25.41-26.92-32.19-36.70-36.36-30.26-22.13-31.84
Depreciation3.833.893.973.963.882.232.160.630.65
Other Funds (Non Cash)3.013.255.357.1612.0415.8314.079.7220.54
Funds from Operations-15.86-18.28-17.60-21.07-20.78-18.30-14.03-11.78-10.65
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.881.16-1.210.550.63-0.24-1.25-4.54-2.74
Cash from Operating Activities-16.75-17.12-18.81-20.53-20.15-18.55-15.28-16.32-13.39
Capital Expenditures-0.01-0.04-0.11-0.37-0.66-9.04-2.69-0.34-0.06
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.006.15-6.150.000.000.00
Purchase of Investments0.000.000.000.000.00-6.150.000.000.00
Sale Or Maturity of Investments0.000.000.000.006.150.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.04-0.11-0.375.49-15.18-2.69-0.34-0.06
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock23.4725.1621.206.25-0.0453.9925.8414.6521.39
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock23.4725.1621.206.25-0.0453.9925.8414.6521.39
Proceedsfrom Stock Options23.4725.1621.20-0.74-0.1747.2613.420.130.19
Issuance or Reduction of Debt, Net-2.21-2.01-1.77-1.56-0.600.53-0.80-0.01-0.01
Change in Long Term Debt-2.21-2.01-1.77-1.56-0.600.53-0.80-0.01-0.01
Issuance of Long Term Debt0.350.350.450.000.791.610.000.000.00
Reduction of Long Term Debt-2.56-2.36-2.22-1.56-1.39-1.08-0.80-0.01-0.01
Net Financing Active Other Cash Flow0.220.220.080.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities21.4923.3719.514.69-0.6454.5225.0414.7921.39
Net Change in Cash4.736.220.59-16.20-15.3020.797.06-1.877.94
Free Cash Flow-16.75-17.15-18.91-20.89-20.79-27.56-17.93-16.50-13.39
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments6.531.896.2810.951.791.92
Short Term Receivables0.000.000.000.000.000.00
Inventories0.270.280.230.300.520.88
Other Current Assets0.710.720.520.340.310.22
Total Current Assets7.502.897.0311.602.623.02
Net Property, Plant & Equipment10.2211.2112.2112.9013.9114.92
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.070.070.100.120.130.14
Other Assets3.563.533.553.543.673.73
Total Assets21.3617.7122.8928.1620.3421.81
Short Term Debt Incl. Current Port. of LT Debt2.702.612.522.442.392.35
Accounts Payable1.020.931.031.061.581.70
Other Current Liabilities1.351.261.491.631.651.45
Total Current Liabilities5.084.815.045.135.625.50
Long Term Debt5.195.906.596.947.578.18
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.120.120.120.120.120.12
Total Liabilities10.4010.8311.7612.2013.3113.81
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity10.966.8711.1415.967.028.00
Total Shareholders Equity10.966.8711.1415.967.028.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity10.966.8711.1415.967.028.00
Total Liabilities & Stockholders Equity21.3617.7122.8928.1620.3421.81
Book Value Per Share0.620.811.321.991.322.84
Tangible Book Value Per Share0.620.801.311.981.302.79
Price to Book Ratio2.263.972.646.970.812.43
Return on Assets-108.91-114.90-97.99-92.16-114.49-102.64
Return on Equity-252.53-305.27-212.12-176.32-328.04-238.64
Return on Invested Capital-35.09-42.79-30.85-26.64-38.81-40.61
Quick Ratio1.420.541.352.200.370.39
Current Ratio1.480.601.392.260.470.55

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-5.67-5.47-5.47-6.10-5.66-6.57
Depreciation0.950.960.960.960.960.97
Other Funds (Non Cash)0.681.040.620.660.211.20
Funds from Operations-4.04-3.47-3.88-4.48-4.50-4.40
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.01-0.56-0.14-0.190.560.03
Cash from Operating Activities-4.03-4.02-4.02-4.67-3.94-4.37
Capital Expenditures0.000.000.00-0.010.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.010.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock9.240.20-0.1114.144.322.18
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock9.240.20-0.1114.144.322.18
Proceedsfrom Stock Options9.240.20-0.1114.144.322.18
Issuance or Reduction of Debt, Net-0.58-0.56-0.55-0.52-0.51-0.50
Change in Long Term Debt-0.58-0.56-0.55-0.52-0.51-0.50
Issuance of Long Term Debt0.000.000.000.350.000.00
Reduction of Long Term Debt-0.58-0.56-0.55-0.87-0.51-0.50
Net Financing Active Other Cash Flow0.000.000.000.220.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities8.67-0.36-0.6513.843.811.68
Net Change in Cash4.64-4.39-4.689.16-0.13-2.69
Free Cash Flow-4.03-4.02-4.02-4.68-3.94-4.37

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.31%0.7M16.4M201.31K
2026-10-154.06%0.7M16.4M237.23K
2026-09-303.62%0.6M16.4M232.43K
2026-09-153.78%0.6M16.4M278.58K
2026-08-314.78%0.8M16.4M316.47K
2026-08-144.34%0.7M16.5M381.31K
2026-07-317.44%1.2M16.1M545.63K
2026-07-154.45%0.7M16.1M508.61K
2026-06-301.63%0.3M16.1M446.13K
2026-06-155.72%0.8M13.4M378.49K
2026-05-291.83%0.2M12.6M330.82K
2026-05-153.46%0.3M7.4M268.77K
2026-04-309.14%0.7M7.8M52.37K
2026-04-156.09%0.5M7.8M54.32K
2026-03-316.03%0.5M7.8M55.36K
2026-03-136.38%0.5M7.8M64.96K
2026-02-276.47%0.5M7.8M67.90K
2026-02-136.47%0.5M7.8M69.02K
2026-01-306.78%0.5M7.7M71.29K
2026-01-155.24%0.4M7.8M74.83K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-03S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-178-KCurrent report2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-02ARSAnnual report to security holders. 2025-09-30SEC
2026-07-02DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-23SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-168-KCurrent report2026-06-14SEC
2026-06-15424B5SEC
2026-05-27RWRegistration Withdrawal RequestSEC
2026-05-19RWRegistration Withdrawal RequestSEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-11SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-138-KCurrent report2026-05-11SEC
2026-05-13424B4SEC
2026-05-11EFFECTEffectiveness filing by commission orderSEC
2026-05-07CORRESPSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08138.00K100
2026-070000
2026-060000
2026-05479.00K200
2026-040000
2026-030000
2026-020000
2026-01200.00K100
2025-1250.00K100
2025-110000

Institutional holders

Manager% owned
RENAISSANCE TECHNOLOGIES LLC3.95%
VANGUARD CAPITAL MANAGEMENT LLC3.75%
CITADEL ADVISORS LLC1.37%
MAI Capital Management0.75%
GEODE CAPITAL MANAGEMENT, LLC0.74%
HRT FINANCIAL LP0.35%
VANGUARD FIDUCIARY TRUST CO0.34%
COMMONWEALTH EQUITY SERVICES, LLC0.32%
BlackRock, Inc.0.30%
BANK OF AMERICA CORP /DE/0.28%

Funds

Fund% owned
VANGUARD TOTAL INTERNATIONAL BOND II INDEX FUND107%
VANGUARD TOTAL INTERNATIONAL BOND INDEX FUND53.21%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.15%
iShares Core International Aggregate Bond ETF3.12%
VANGUARD EXTENDED MARKET INDEX FUND0.59%
Fidelity Extended Market Index Fund0.35%
Fidelity Series Total Market Index Fund0.07%
Fidelity Total Market Index Fund0.07%
Ultra-Small Company Market Fund0.05%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. CVM. Cached 15 minutes.